Psychedelicmarketcap

been working on this for a while: PsychedelicMarketCap.com if you're following #psychedelic stocks, this should help 📊🍄👩‍🔬

@simchaantwerpen @redlightholland best ticker for shure 😵‍💫

@Psymarketcapcom @redlightholland $TRIP $TRUFF

what's the one psychedelic stock you're most confident in long term? Whats the ticker? 👀🍄

2026 prediction: at least one psychedelic therapy gets FDA approval this year and nobody outside this niche will even notice. the mainstream is always late.

J&J's SPRAVATO is already doing $1B+ in revenue. it's a ketamine derivative. and most people still think psychedelic medicine is "years away." it's literally here.

The time for psychedelics is now. $ATAI

COMP006, CYB003, GH001, BPL-003 — if none of these mean anything to you, you're not paying close enough attention to what's coming in psychedelic pharma. psymarketcap.com

tired of checking 6 different sites to track psychedelic stocks. so we built one place for all of it. prices, market caps, company data — psymarketcap.com

@APsychedelics @sunterry__ Two hours to cure depression doesn't sound bad at all to me

Two hours in ✋🤯 Art by @sunterry__

@APsychedelics $DFTX (Acid) vs $CMPS (Shrooms)

Acid vs Mushrooms 🤯

Are you bullish or bearish on psychedelic stocks this year? 👀🍄

Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026 $CMPS ir.compasspathways.com/News--Events-/…

the gap between psychedelic research headlines and actual stock performance is wild. breakthrough therapy designations don't pay the bills. phase 3 results do.

@bryan_johnson DMT stocks = huge

I'm experimenting with 5-MeO-DMT because it may be most underrated longevity molecule no one is talking about. + Accelerated neurogenesis: a single dose more than doubled brain cell proliferation and neuronal regeneration in the hippocampus within 12 hours, alongside measurable increases in synaptic density and firing frequency in rodent models. + Proteomic reorganization: in human cerebral organoids, 5-MeO-DMT triggers rapid proteomic shifts favoring cellular reorganization and synapse formation. Early evidence of structural brain renewal at the molecular level. + Default Mode Network reset: The DMN calcifies with age locking us into rigid, repetitive patterns of thought. 5-MeO-DMT disrupts these patterns, restoring bottom up connectivity between sensory and creative brain regions. A forced return to neurological flexibility and youthfulness. + Systemic anti-inflammation: suppresses pro-inflammatory cytokines (IL-1β, IL-6, TNF-alpha) while upregulating IL-10, the anti-inflammatory signal. Mediated through the Sigma-1 receptor, suggesting a mechanism distinct from other psychedelics.

Know what you hold. 🧠 $ATAI analysts mean target: 13.45$

$DFTX Unusual options activity detected

$DFTX $ATAI $CMPS $HELP I wanted to bring back the chart below from an article in The Economist in 2010 evaluating different drugs and their respective safety profiles. Very interesting to see the three least dangerous spots are occupied by psychedelic drugs that are still to this day ‘Schedule 1’ substances that are “considered to have a high potential for abuse, no currently accepted medical use in treatment”. A decade and a half later and these drugs may soon be FDA approved medicines. This industry is just getting started. Extremely bullish.

@filipsamardzicc Yes $DFTX is extremely undervalued for what's coming.

psymarketcap.com does list the mean analyst targets of psychedelic stocks.

“It will help Minnesotans who are struggling with a wide variety of mental illnesses from substance use disorder, depression, PTSD, anxiety, chronic pain and more” $CMPS $ATAI marijuanamoment.net/minnesota-lawm…

@bryan_johnson 🍄

My next longevity experiment: 5-MeO-DMT.